Valye reports for unlimited access

Gulf Coast Ultra Deep Royalty Trust holds overriding royalty interests in the onshore Highlander subject interest, targeting deep hydrocarbon formations in South Louisiana. The trust's income derives from royalties on production, but it does not operate or control the underlying assets. The only producing well was shut in and abandoned in early 2024, and future income depends on successful drilling and production from new wells. The trust relies on contributions and loans from HOGA to cover administrative expenses and maintain liquidity. The trust units trade on an OTC market with limited liquidity and are subject to penny stock regulations.

Toppoint Holdings Inc. operates as a truckload services and solutions provider specializing in the recycling export supply chain. The company transports waste paper, scrap metal, and wooden logs from large waste companies, recycling centers, and commodity traders to ports in Newark, NJ and Philadelphia, PA. It also provides import transportation services at these ports, moving cargo-filled containers to customer locations. Toppoint has expanded its footprint domestically into Florida and Maryland markets and internationally into Mexico and Texas, with plans to explore Latin America, including Peru. The company serves a broad client base including Fortune 500 waste companies and over 207 recycling centers and commodity traders across more than 1,000 locations. Toppoint emphasizes integrated transportation solutions and high-quality service. The company completed its initial public offering in January 2025, raising $10 million. It operates one reportable segment and evaluates performance primarily through net income.

SOLV Energy, Inc. is a publicly traded company on Nasdaq (ticker MWH) that completed its initial public offering in early 2026. The company is engaged in the clean energy sector, advancing solar energy projects such as the Blossom Solar Project in Ohio and the Nightfall Solar Project in Texas. It filed an amended annual report (10-K/A) for the fiscal year ended December 31, 2025, which includes standard regulatory disclosures and auditor consents. The company has publicly reported its financial results for 2025 and maintains active communication through press releases.

MODIV INDUSTRIAL, INC. is a real estate investment trust primarily engaged in acquiring, managing, and disposing of industrial properties. The company’s portfolio includes properties leased to tenants such as Fujifilm Dimatix, Inc. and Northrop Grumman Systems Corporation, with lease terms extending several years. It utilizes a credit facility comprising a revolving line of credit and a term loan, with interest rate swaps to manage exposure to floating rates. The company actively manages its portfolio through acquisitions and dispositions, including a recent acquisition in Jacksonville, Florida, and sales of properties in New York and Washington. Capital expenditures focus on tenant improvements and property maintenance. The company reports operating performance using Funds from Operations (FFO) and Adjusted Funds from Operations (AFFO) metrics. Market conditions such as inflation, interest rates, and supply chain disruptions are acknowledged as ongoing challenges [S1][N1][N4].

Medicus Pharma Ltd. is a biotechnology company focused on accelerating clinical development of novel therapeutic assets. Its key product candidates include SkinJect, a patch technology for non-invasive treatment of basal cell carcinoma, and Teverelix, a drug candidate for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate. The company acquired Antev in 2025, which added Teverelix to its pipeline. Medicus Pharma is in early clinical stages with ongoing Phase 2 trials and has no current product revenues or customer contracts. The company relies on external contract research organizations and is building its operational and commercial capabilities. It is listed on Nasdaq and recently celebrated its one-year anniversary on the exchange.

Nkarta, Inc. pioneers the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, aiming to provide broadly accessible treatments for autoimmune diseases. The company's lead candidate, NKX019, is a CAR NK cell therapy targeting CD19, currently in Phase 1 trials for multiple autoimmune indications including lupus nephritis, systemic sclerosis, and myasthenia gravis. Nkarta's platform leverages healthy donor NK cells, enabling scalable manufacturing and potential outpatient administration. The company has proprietary technologies addressing NK cell expansion, engineering, persistence, and cryopreservation challenges. Nkarta operates two cGMP manufacturing facilities in South San Francisco to support clinical and potential commercial supply. The company has incurred significant losses since inception and continues to invest in clinical development and manufacturing capabilities [S1].

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) solutions that include federally certified communications management, identity management, interactive billing and analytics, and Information Technology as a Service (ITaaS). The company serves primarily U.S. federal government agencies, including the Department of Homeland Security, and commercial enterprises. Its TMaaS offerings are delivered through a flexible 'As-a-Service' model designed for scalability and configurability. WidePoint's managed services encompass telecom lifecycle management, mobile and identity management, digital billing and analytics, and IT services such as cybersecurity, cloud, and network operations. The company holds multiple government contracts and contract vehicles, including the DHS Cellular Wireless Managed Services 2.0 ID/IQ contract and the Navy Spiral 4 contract. WidePoint operates proprietary solutions hosted in multiple data centers in North America and Europe, with plans to migrate more customers to the cloud. The company competes in a fragmented market with various competitors across its service segments but claims a competitive advantage by offering all four critical TMaaS services. Sales approaches include direct sales, partnerships with large systems integrators, and strategic partnerships leveraging reseller networks. The sales cycle is typically long, often exceeding 12 months from initial engagement to contract award and implementation. Financially, WidePoint reported $150.5 million in revenue for fiscal year 2025, with a net loss of $2.75 million and a gross margin of 14%. The company maintains a revolving credit facility and reported positive operating cash flow in 2025.

TELA Bio, Inc. develops and commercializes innovative soft-tissue reconstruction solutions designed to optimize clinical outcomes by preserving and restoring the patient’s own anatomy. Its flagship products, the OviTex and OviTex PRS reinforced tissue matrices, combine biologic material derived from ovine rumen with polymer fibers to provide strength, stability, and controlled stretch for use in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company’s products are FDA-cleared and manufactured exclusively by Aroa in New Zealand under a long-term supply agreement. TELA Bio markets primarily in the U.S. through a direct sales force and has established contracts with national group purchasing organizations and integrated delivery networks to increase hospital access. The company invests in clinical studies and product development to enhance its portfolio and expand indications. Financially, TELA Bio reported $80.3 million in revenue and a net loss of $38.8 million for the year ended December 31, 2025, with strong liquidity ratios indicating a solid short-term financial position [S1].

Immersion Corporation is a publicly traded company incorporated in Delaware, with its common stock listed on the Nasdaq Global Market under the symbol IMMR. The company is headquartered in Aventura, Florida. It operates within the computer peripheral equipment industry, as indicated by recent industry-focused news coverage. The company maintains a strong liquidity position with current assets significantly exceeding current liabilities as of the latest quarterly report. It reported a net loss and negative earnings per share for the quarter ended July 31, 2025. The Board has declared a quarterly cash dividend, reflecting a capital allocation strategy that includes shareholder returns. Immersion has a history of filing detailed SEC reports including annual and quarterly filings with comprehensive disclosures on financials, governance, and securities.

United Security Bancshares is a bank holding company headquartered in Fresno, California, operating through United Security Bank. The Bank provides a comprehensive range of commercial banking services including deposit accounts, lending products such as commercial, real estate, construction, agricultural, and consumer loans, and specialized services like online and mobile banking. The Bank's operations are concentrated in Fresno, Madera, Kern, Santa Clara, and other California counties, competing with numerous financial institutions. The company maintains regulatory compliance under the Federal Reserve Board, California DFPI, and FDIC insurance. The loan portfolio is diversified but has a high concentration in commercial real estate loans. The company also manages real estate holdings through a subsidiary and has issued Trust Preferred Securities via a special purpose entity. The company’s stock is listed on Nasdaq under the ticker UBFO.

Leef Brands Inc. is a publicly traded cannabis company headquartered in California, listed on the Canadian Securities Exchange under the ticker LEEF. The company operates a vertically integrated business model encompassing cultivation, extraction, manufacturing, and retail. Its core operations include a large-scale cultivation property, Salisbury Canyon Ranch, with 179.9 licensed acres, and advanced extraction facilities with ethanol, hydrocarbon, and solventless extraction capabilities. Leef Brands supplies bulk cannabis concentrates, including distillates, live resin, and rosin, primarily to licensed cannabis brands in California and New York. The company holds multiple state licenses, including a Type 7 manufacturing license in California and a Type 1 processor license in New York. Leef Brands has expanded extraction capacity and entered the New York market, reporting revenue growth and margin expansion in 2025. The company also pursues a Bitcoin treasury strategy, accumulating Bitcoin organically through operations. It employs approximately 81 full-time employees and operates one retail location that does not materially contribute to revenue.

VANJIA CORP is a smaller reporting company with limited publicly available information about its business model, industry, or operations. The company has not reported revenue in recent periods and recorded a net loss for the fiscal year ended December 31, 2025. Financial disclosures indicate a strong liquidity position based on cash and current assets relative to liabilities, although some liability data is outdated. The company is subject to routine legal proceedings typical for its business but management does not expect material adverse effects from these matters.

SOLV Energy, Inc. is a Delaware-based company engaged in the clean energy sector, with a focus on solar energy projects. The company completed its initial public offering in early 2026 and is listed on Nasdaq under the ticker MWH. It operates through its subsidiary SOLV Energy Holdings LLC and has established a revolving credit facility to support its operations and growth. The company has announced financial results for the full year 2025 and is advancing its national clean energy portfolio with projects in Ohio and Texas. Governance structures including a board of directors and equity incentive plans have been put in place following the IPO.

STRATA Skin Sciences, Inc. develops and markets medical devices for dermatologic conditions, including psoriasis, vitiligo, atopic dermatitis, and acne. Its flagship product line, the XTRAC excimer laser systems, delivers targeted UVB phototherapy and is FDA-cleared for multiple skin disorders. The company’s business model in the U.S. centers on a recurring revenue approach, placing devices in physician offices at no upfront cost and generating revenue based on treatment usage. STRATA also markets the TheraClear Acne Therapy System and has transitioned international sales from distributor-based to direct contracts in multiple countries. Manufacturing occurs at an ISO 13485 certified facility in California. The company faces competition from pharmaceutical and device companies offering alternative treatments. STRATA’s financial position shows ongoing operating losses, liquidity constraints, and stock delisting from Nasdaq. Regulatory compliance, reimbursement policies, and trade tariffs are material factors influencing operations.

Inhibitor Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapies primarily for basal cell carcinomas in Gorlin's syndrome, prostate, and lung cancers. The company utilizes a proprietary formulation of itraconazole and is engaged in pre-clinical and potential clinical trial activities. It has no commercial products or revenues to date and relies on third-party partnerships for marketing and distribution. The company’s operations are dependent on a small management team and face significant risks typical of early-stage biotech firms, including regulatory, financial, and operational challenges. Recent capital raises are intended to support ongoing development and corporate activities.

CaliberCos Inc. is an alternative asset manager with a 16-year history, managing over $2.6 billion in assets comprising $0.8 billion in assets under management and $1.9 billion in assets under development. The company invests in private real estate funds and digital infrastructure assets, primarily Chainlink tokens, aiming to enhance shareholder value for accredited investors. Its real estate focus includes multi-family residential, industrial, and hospitality assets in growth markets such as Arizona, Colorado, and Texas. CaliberCos operates a vertically integrated platform providing asset management, development, brokerage, and advisory services, targeting middle-market projects typically between $5 million and $50 million. The company is developing the Caliber Hospitality Trust (CHT), a hotel investment vehicle using an UPREIT strategy. Revenue is generated from various fees including fund management, financing, development, brokerage, and performance allocations. The digital asset treasury strategy complements the real estate platform by providing exposure to blockchain infrastructure and staking yield. The company has 50 employees and has recently undertaken a 1-for-20 reverse stock split. Financial results for 2025 show a decline in revenues and a net loss, with liquidity challenges noted in the filings. Recent news highlights include joint ventures in hospitality development and agreements with Hyatt for hotel projects.

Indigo Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in June 2024. Its business model centers on raising capital through an initial public offering and private placements to fund a future business combination with one or more target companies. The company completed its IPO in July 2025, issuing units consisting of ordinary shares and rights, and deposited net proceeds into a trust account invested in low-risk government securities or money market funds. It has not generated any operating revenues and does not expect to do so until after completing its initial business combination. The company targets established, profitable businesses with growth potential but is not restricted to any industry or geography. Management and the Sponsor are affiliated, and the company may seek additional financing to complete its business combination if necessary. The company must complete a business combination by April 2027 or face mandatory liquidation.

Comscore, Inc. provides data and analytics services that measure advertising effectiveness, content consumption, and audience behavior across various media platforms globally. The company offers solutions primarily through its Content & Ad Measurement segment, which includes Syndicated Audience and Cross-Platform products, and its Research & Insight Solutions segment. Revenue is recognized mostly over time from long-term contracts with customers across multiple geographic regions, with the United States representing the largest market. Comscore's business model relies on proprietary data collection, analytics technology, and strategic partnerships to deliver insights to advertisers, media companies, and marketers. The company has recently expanded its capabilities through partnerships incorporating AI and person-level data, and it holds industry certifications such as full JIC certification for national TV measurement.

HWH International Inc. was formed in 2021 and completed a business combination in early 2024, transitioning to an early-stage emerging growth company. Its business model centers on the Hapi Marketplace, a multi-category consumer marketplace launched in the U.S. with plans for Asian expansion, and Hapi Cafés, which are physical locations designed to foster community and promote affiliated products and services. The company is also developing educational programs under the Hapi Wealth brand and expanding into robotics products. It has undergone corporate restructuring including a reverse stock split and a legal domicile change to Nevada. The company relies on capital raises and related-party financing to support operations and growth initiatives.

NovelStem International Corp. transitioned from a media company to a biotechnology holding company in 2018 with the acquisition of NewStem Ltd, an Israeli biotech firm focused on stem cell-based technology for anti-cancer therapies. NewStem developed a proprietary bio-platform based on haploid human embryonic stem cells for genome-wide screenings and oncology drug discovery, including a personalized diagnostic device for early detection of chemotherapy resistance. NewStem's diagnostic device received CE Mark from the European Medicines Agency but lacks FDA approval. NewStem was liquidated in October 2025, with the license and technology reverting to Yissum Research Development Company, while NovelStem retains a financial interest in future monetization of the license. The company also held a 50% interest in NetCo Partners, owner of the 'Net Force' entertainment franchise, which was sold in May 2025 to settle litigation funding liabilities. Currently, NovelStem conducts no other business and relies on consultants for operations. The company reported net income in 2025 after prior losses but faces liquidity constraints and depends on shareholder support and successful monetization of its license rights.

Noodles & Company is a publicly traded restaurant company specializing in noodle-based cuisine. It operates under the ticker NDLS on the Nasdaq Global Select Market. The company has experienced financial losses in recent periods and faces liquidity challenges as reflected in its low current and cash ratios. It has taken corporate actions such as a reverse stock split to comply with listing requirements and has attracted minority investment from Galloway Capital Partners. The company maintains active investor communications through earnings calls and press releases.

TXO Partners, L.P. is a Delaware limited partnership engaged in the exploration, development, and production of oil, natural gas, and natural gas liquids in North America. Its operations are concentrated in three main U.S. basins: the Permian Basin (New Mexico and Texas), the San Juan Basin (New Mexico and Colorado), and the Williston Basin (Montana and North Dakota). The company operates as a single reporting segment and sells production to multiple purchasers, with some customers accounting for significant portions of revenue. TXO employs commodity derivative contracts to hedge price risks and uses non-GAAP measures such as Adjusted EBITDAX and Cash Available for Distribution to assess financial performance. The company has a revolving credit facility with a borrowing base increased to $410 million and had borrowings of $264 million as of September 30, 2025. Recent strategic activities include the acquisition of assets from White Rock Energy, LLC and the planned sale of assets owned by its joint venture, Cross Timbers Energy, LLC.

Williams-Sonoma, Inc. operates in the specialty home furnishings and kitchen products retail sector, combining e-commerce, retail stores, and direct-mail catalogs to reach customers. The company competes on brand strength, product quality, customer service, and a digital-first strategy. It designs proprietary products and manages a global supply chain to deliver high-quality, durable merchandise. The business is seasonal, with a peak selling period from October through January. Williams-Sonoma employs nearly 20,000 associates and invests in their development and well-being. The company holds extensive intellectual property assets including trademarks, patents, and copyrights. It maintains liquidity with over $1 billion in cash and equivalents and reported strong net income and earnings per share for fiscal 2025. The company faces competitive pressures, supply chain risks, cybersecurity threats, and challenges related to global expansion and regulatory compliance.

Paychex, Inc. operates as a human capital management (HCM) company providing a comprehensive range of technology and advisory solutions in HR, payroll, employee benefits, insurance, and retirement services. The company serves a diverse client base across the U.S. and parts of Europe, with approximately 800,000 clients as of mid-2025. Its product offerings include cloud-based SaaS platforms such as Paychex Flex for small and medium businesses, Paycor for larger businesses, and SurePayroll for small business self-service. Paychex also offers HR outsourcing through ASO and PEO models, with PEO services involving co-employment and insurance risk assumption. The company integrates advanced analytics and AI into its platforms to enhance client experience and operational efficiency. Paychex markets its solutions through direct sales, digital marketing, and referral channels including CPAs and banks. The company completed the acquisition of Paycor in April 2025 to strengthen its upmarket presence and AI capabilities.

Interlink Electronics Inc. develops and manufactures advanced sensing technologies, including force-sensing resistors (FSR®), piezoelectric sensors, and electrochemical gas sensors. The company integrates proprietary materials science, embedded electronics, firmware, and software to deliver scalable human-machine interface (HMI) and environmental sensing solutions. Its products serve diverse markets such as medical, industrial, automotive, consumer electronics, wearables, and environmental monitoring. Interlink operates manufacturing facilities in China, the United States, and Scotland, and maintains global distribution and sales offices. The company focuses on custom-engineered solutions alongside standard products, often becoming a sole-source supplier due to specialized designs and regulatory approvals. Its sales cycle can extend over months or years, reflecting the technical complexity and application-specific nature of its offerings.

Founded in 1990, Ulta Beauty, Inc. developed a unique specialty retail concept combining a broad range of beauty products and services in a convenient, welcoming environment. It targets beauty enthusiasts passionate about self-expression and experimentation. Ulta Beauty operates primarily in the U.S. with 1,505 stores and internationally through Space NK and partnerships in Mexico and the Middle East. The company offers approximately 29,000 products across categories including cosmetics, fragrance, skin care, hair care, wellness, and salon services. Its business model integrates physical stores, digital platforms, and a loyalty program that drives customer engagement and insights. The company’s strategic focus is on driving core business growth, scaling new accretive businesses, and optimizing operations and culture to sustain competitive advantages in a growing beauty and wellness market [S1][S2].

Vivani Medical, Inc. develops implantable drug delivery technologies targeting chronic diseases such as type 2 diabetes and obesity. Its lead programs include GLP-1 receptor agonist implants, with clinical trials underway for exenatide and semaglutide implants. The company also has a subsidiary, Cortigent, focused on brain-implant technology, which is planned for spin-off as an independent Nasdaq company. Vivani's business model centers on advancing clinical development, securing regulatory approvals, and preparing for commercialization of its implantable therapies. The company finances its operations through equity offerings and strategic partnerships.

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing treatments for neurological and pulmonary diseases. The company is advancing IKT-001, its lead drug candidate, into a global pivotal Phase 3 clinical trial for Pulmonary Arterial Hypertension (PAH). The Phase 3 study, named IMPROVE-PAH, is designed as a two-part adaptive trial with endpoints focused on pulmonary vascular resistance and 6-minute walk distance. The company completed a public offering in late 2025, raising net proceeds of approximately $93.6 million. As of the fiscal year ended December 31, 2025, Inhibikase held strong liquidity with cash and short-term investments exceeding $218 million and maintained a high current ratio. The company reported a net loss of $48.3 million for the year. The Board of Directors actively oversees risk management, including cybersecurity, with no history of breaches. The company is not currently involved in any material litigation.

LB Pharmaceuticals Inc, headquartered in New York, is focused on developing novel therapies for neuropsychiatric disorders. Its lead candidate, LB-102, is in late-stage clinical development for schizophrenia and bipolar depression, with plans for further trials in major depressive disorder. The company has not yet generated product revenue and relies on capital raised through equity offerings, including a 2025 IPO and a 2026 private placement, to fund its operations. Research and development activities are central to its business, with expenses primarily related to clinical trials, formulation, manufacturing, and regulatory affairs. The company maintains a strong liquidity position with over $295 million in cash and marketable securities as of the end of 2025. LB Pharmaceuticals operates as a single segment and depends on third-party vendors for clinical development support. It faces typical risks for early-stage biopharmaceutical companies, including regulatory approval uncertainties and the need for additional financing.

SANUWAVE Health, Inc. is a publicly traded company listed on The Nasdaq Stock Market under the ticker SNWV. The company reported $44.05 million in revenue and $11.813 million in net income for the fiscal year ended December 31, 2025. It maintains a current ratio of 1.38 and cash ratio of 0.67, indicating moderate liquidity. SANUWAVE has recently achieved record quarterly revenues, including a 29–30% year-over-year increase in Q4 2025 preliminary revenue and a 41% increase in Q2 2025 preliminary revenue. The company has secured a $23 million term loan and a $5 million revolving credit facility to support its operations. Management has disclosed a restatement of prior financial periods due to historical state sales and use tax liabilities, which impacts reported liabilities and expenses. The company faces operational risks related to information technology and cybersecurity.

Microbot Medical Inc. develops and commercializes medical robotic systems, with its primary focus on the LIBERTY® Endovascular Robotic Surgical System. The company transitioned from a research and development stage to a commercial-stage entity in 2025. Microbot depends heavily on the successful commercialization of LIBERTY, which requires establishing manufacturing capabilities through third parties, building sales and marketing infrastructure, and obtaining regulatory clearances. The company has not yet generated significant revenues and expects to incur operating losses as it advances commercialization efforts. Market acceptance depends on demonstrating safety, efficacy, cost-effectiveness, and gaining acceptance from medical professionals and payors. Microbot holds key patents in the U.S. and China and has received FDA clearance for LIBERTY. The company is listed on NASDAQ under the ticker MBOT.

Identiv, Inc. is a technology company specializing in RFID and IoT solutions, serving various industries including emerging markets such as medical devices. The company sold its physical security business in 2024, receiving significant cash proceeds to support its growth and operational strategies. Manufacturing is concentrated in a single facility in Thailand, with additional reliance on contract manufacturers internationally. Identiv distributes its products largely through channel partners, which impacts direct customer visibility. The company operates in a competitive environment with increasing manufacturing capacity and pricing pressures, particularly from low-cost competitors. Financially, Identiv reported a net loss in 2025, with liquidity remaining strong. The company faces risks from supply chain disruptions, tariff impacts, and fluctuations in customer demand and market adoption of RFID technology [S1].

INNOVATE Corp. is a publicly traded company listed on the New York Stock Exchange under the ticker VATE. The company reported full-year 2025 revenue of approximately $1.25 billion and a net loss of $60.6 million. It holds significant cash and current assets but has current liabilities exceeding current assets, resulting in liquidity ratios below 1. The company has engaged in refinancing its indebtedness to extend debt maturities. INNOVATE Corp. supports its portfolio company DBM Global Inc. with a substantial credit facility and receives dividend distributions from it. The company has also received FDA approval for its MediBeacon® Transdermal GFR System, indicating involvement in medical diagnostic technology. News coverage associates the company with sectors including construction, aerospace, and defense, though explicit sector classification is not disclosed.

enVVeno Medical Corp specializes in developing innovative bioprosthetic tissue-based medical devices aimed at treating venous disease, particularly severe Chronic Venous Insufficiency (CVI) of the deep venous system in the leg. The company initially developed the VenoValve, a surgical replacement venous valve, which did not receive FDA approval following a non-approvable letter in August 2025. Subsequently, enVVeno shifted focus to the enVVe System, a next-generation, minimally invasive, transcatheter-based venous valve designed to address prior FDA concerns and broaden clinical adoption. The enVVe System has completed pre-clinical testing, and the company is engaging with the FDA regarding pivotal clinical trials. enVVeno operates an ISO-certified manufacturing facility in Irvine, California, and holds multiple patents related to its technologies. The company has incurred significant operating losses and currently has no revenue, funding operations through equity and debt financings. enVVeno faces regulatory, clinical, and capital-raising challenges as it advances its product pipeline.

SKYX Platforms Corp. is a Florida-incorporated company specializing in advanced-safe-smart platform technologies for light fixtures, ceiling fans, and other electrically wired products. Their technology enables quick, safe plug-and-play installation without handling hazardous wires and includes smart home features controlled via a proprietary app. The company also markets third-party home lighting and furnishings. SKYX operates multiple offices across the U.S. and China. The business model combines product innovation, patent development, and strategic partnerships to expand market penetration in the smart home sector.

BioRestorative Therapies, Inc. develops cell and tissue-based therapeutic products primarily involving adult stem cells. The company’s lead program is the Disc/Spine Program, with BRTX-100 as the lead investigational product. BRTX-100 is an autologous mesenchymal stem cell therapy intended for non-surgical treatment of chronic lower back pain due to degenerative disc disease and chronic cervical discogenic pain. The company is conducting Phase 2 clinical trials for BRTX-100 and has received FDA Fast Track designation. Preliminary clinical data indicate safety and potential efficacy in pain reduction and functional improvement. The company is also developing the ThermoStem Program targeting metabolic disorders using brown adipose derived stem cells and exosomes. Additionally, BioRestorative operates a commercial biocosmeceutical platform with a proprietary cell-based serum for cosmetic use. The company has licensed a curved needle device for cell delivery pending FDA approval. The company has not generated significant revenues to date and relies on equity financing to fund operations and clinical development. As of December 31, 2025, the company had a working capital deficit and reported net losses, raising substantial doubt about its ability to continue as a going concern without additional financing.